Kestra Private Wealth Services LLC Buys New Position in BioNTech SE (NASDAQ:BNTX)

Kestra Private Wealth Services LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 8,883 shares of the company’s stock, valued at approximately $938,000.

Several other large investors have also bought and sold shares of the company. CWM LLC boosted its position in shares of BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the period. Covestor Ltd acquired a new position in shares of BioNTech in the 3rd quarter valued at $32,000. UMB Bank n.a. acquired a new position in shares of BioNTech in the 4th quarter valued at $50,000. Ramirez Asset Management Inc. acquired a new position in shares of BioNTech in the 3rd quarter valued at $76,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of BioNTech by 42.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 840 shares of the company’s stock valued at $91,000 after purchasing an additional 250 shares during the period. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 0.5 %

BNTX opened at $92.72 on Friday. BioNTech SE has a fifty-two week low of $85.21 and a fifty-two week high of $125.83. The business has a 50-day moving average of $90.54 and a 200-day moving average of $95.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The company has a market capitalization of $22.04 billion, a PE ratio of 22.50 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. Equities research analysts forecast that BioNTech SE will post -1.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of recent analyst reports. The Goldman Sachs Group decreased their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. JPMorgan Chase & Co. reduced their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research note on Friday, March 22nd. HC Wainwright reissued a “buy” rating and issued a $107.00 price objective on shares of BioNTech in a research note on Wednesday, April 17th. BMO Capital Markets reduced their price objective on BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research note on Thursday, March 21st. Finally, UBS Group reduced their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, BioNTech has an average rating of “Hold” and a consensus price target of $120.40.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.